Our journey to become a science-led company
Maria Conde and Matthias De Langhe, Associate Scientists, Ghent, Belgium (c) Simon Buxton

Our journey to become a science-led company

Almost four years ago exactly, we presented a six-year strategy aimed at putting Sanofi back on the map of the most innovative pharma companies in the industry.

It was a different world then and we were a different company. Four years later, we’ve made more progress than I could have ever imagined, and we are closer than ever to becoming the Sanofi we aspire to be.

Today we are providing insights about our ambitions to become a science-led company. How? By charting a new scientific course in immunology, taking ambitious shots on goal for patients, and unlocking the potential of technology and Artificial Intelligence in R&D.

A new scientific course in immunology

Since 2020, our R&D teams have been moving fast to reshape our pipeline. We have had major successes, as well as some setbacks – all part of our journey in trying to do things never done before for patients.

One of the areas where we are clearly focused is immunology. Building on our longstanding expertise in vaccines to protect the immune system and our recently developed expertise in addressing chronic inflammatory diseases with medicines, we have expanded our immunology focus to adjacent areas connected to the immune system, including neuro-inflammation, transplant and type 1 diabetes.

Building an industry-leading immunology pipeline able to deliver a steady and sustainable stream of molecules takes determination and time. Whilst the solid foundations we built since 2020 allowed us to roughly quadruple the value of our pipeline, we’ll keep pushing ourselves forward, in line with our company’s purpose.

Ambitious shots on goal for patients

Since early 2023, Sanofi has had the most productive scientific news flow in its history, with promising results for many early and mid-stage molecules addressing serious, chronic diseases. This allows us to move toward building a development-driven organization, with the hope to turn up the dial on turning breakthrough research into realities for patients.

Over the next couple of years, we’ll step up our investments to increase our phase 3 projects by 50%, including 10 trials expected to start next year for assets that could potentially transform the practice of medicine for multiple diseases.

Since 2020, we have been able to make a positive difference in the life of millions of people by launching therapies for diseases like hemophilia A, atopic dermatitis, asthma and respiratory syncytial virus. Looking ahead, we’ll keep doubling down in these diseases and continue expanding our focus on multiple sclerosis, and in newer areas like COPD and T1 diabetes, amongst others.

Technology and AI in R&D

We are also going “all in” on Artificial Intelligence. Not because AI has become a trendy topic, but because we clearly see its long-term value and in fact have just scratched the surface of how we use this disruptive technology to achieve our scientific ambitions.

For example, AI-enabled screening can sift through billions of possible molecules, helping our scientists to shorten the search to find disease drivers and potential drug candidates. AI-driven patient segmentation can help improve the design of clinical studies. Large Language Models can accelerate the drafting of regulatory reports…and there are countless other ways in which AI can and already is being applied across our value chain.

That includes how we are leveraging AI to transform how we manage our R&D portfolio. Our in-house Plai app, which correlates more than 1 billion data points, empowers our R&D teams by giving them unique insights to help them make better, faster and smarter decisions every day.

Yes, we’ve come a long way since 2020, and yes, we still have a long way to go. But we at Sanofi remain steadfast in our commitment to make the right choices for the long-term future of this great company, driven by our ambition to transform the practice of medicine for people around the world.



Osama Maaloul

HR and Talent Acquisition Manager

2 个月

Thanks for Sharing Tarkan

回复
SALIK SHAIKH

Quality control chemist and R&D scientist | Research scientist-2 | 11+ years of experience in QC and R&D | M.Sc.Analytical Chemistry

1 年

Inspiring

Ram Deuja

Senior scientific sales executive at Sanofi

1 年

Best of luck X sanofi field force from Nepal.

Dr. Tanvir Uddin Ahmed

Deputy Director (Hospital Administration)

1 年

Once I was a proud member of Sanofi (BD). Still proud of that. Keep up the good work....

Jit Chakraborty

Key Accounts Manager at Novonordisk

1 年

Great to hear...

回复

要查看或添加评论,请登录

Paul Hudson的更多文章

  • Who Ignites Your Potential?

    Who Ignites Your Potential?

    It’s the question at the center of our Paris 2024 campaign. Maybe it’s winning gold, or maybe it’s discovering the next…

    28 条评论
  • Shining a Light on Science and Innovation

    Shining a Light on Science and Innovation

    2024 will be a year unlike any other for Sanofi. There are many reasons for this.

    31 条评论
  • Celebrating Sports, Spirit and Shared Values

    Celebrating Sports, Spirit and Shared Values

    2023 was a pivotal year for Sanofi. We made great strides in doing what we do best: chasing the miracles of science to…

    25 条评论
  • Giving our people the chance of a lifetime to give back

    Giving our people the chance of a lifetime to give back

    Next summer, all eyes will be on France for the Olympic and Paralympic Games Paris 2024. As thousands of athletes and…

    36 条评论
  • We Are Only as Good as the Sum of Our Parts

    We Are Only as Good as the Sum of Our Parts

    If you type “teamwork + quote” into Google, it’s likely you’ll end up finding a great quote from Michael Jordan. No…

    30 条评论
  • Let’s Fly the Meningitis Flag

    Let’s Fly the Meningitis Flag

    When I joined Sanofi in September 2019, I was excited about diving into the world of prevention and vaccines. Four…

    34 条评论
  • 1 Year to Paris 2024: Ready, Set, Go!

    1 Year to Paris 2024: Ready, Set, Go!

    When we first announced our partnership with the Olympic and Paralympic Games Paris 2024, some people may have…

    60 条评论
  • ASCO 2021: Advancing science together to combat cancer

    ASCO 2021: Advancing science together to combat cancer

    Where will you be early June? My body will be in Paris, but my mind will be in Chicago. The American Society of…

    17 条评论
  • Our commitments to society: We can do more

    Our commitments to society: We can do more

    Shortly after I became CEO in September 2019, I undertook a three-month, worldwide listening tour around the company to…

    83 条评论
  • Rare Disease Day: Our commitment to patients, science, and society

    Rare Disease Day: Our commitment to patients, science, and society

    Every year at end of February, the global health community recognizes rare disease day to help raise awareness of rare…

    26 条评论

社区洞察

其他会员也浏览了